AI-Designed Drug Rentosertib Shows Proteomic Aging Clock Reductions
A phase-2a trial of the AI-discovered drug rentosertib in idiopathic pulmonary fibrosis patients reveals intriguing biomarker changes, but experts urge caution over interpreting proxy signals as true aging reversal.